Immunohistochemical study of matrix metalloproteinases and their inhibitors in pure and mixed invasive and in situ ductal carcinomas of the breast

Human Pathology

Volumn 41, Issue 7, 2010, Pages 980-989

  Gonzalez, Luis O ^a,b   Junquera, Sara ^a   del Casar, Jose M ^a,b   González, Lucía ^a   Marín, Laura ^a   González Reyes, Salomé ^a   Andicoechea, Alejandro ^a,b   González Fernández, Raquel ^c   González, José M ^a   Pérez Fernández, Román ^c   Vizoso, Francisco J ^a,b  

^a HOSPITAL DE JOVE   (Spain)

^b DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

^c UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

Breast cancer; Ductal carcinoma in situ; Matrix metalloproteases; Metalloprotease inhibitors; Tissue arrays; Tumor invasion

Indexed keywords

COLLAGENASE 3; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRILYSIN; MATRIX METALLOPROTEINASE 14; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 3;

ADULT; ARTICLE; CANCER GROWTH; CANCER INVASION; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; FIBROBLAST; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MIXED TUMOR; MONONUCLEAR CELL; PROTEIN EXPRESSION; STROMA CELL; TISSUE MICROARRAY;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASES; MIDDLE AGED; NEOPLASM INVASIVENESS; TISSUE INHIBITOR OF METALLOPROTEINASES; TUMOR MARKERS, BIOLOGICAL;

EID: 77953285948     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2009.08.027     Document Type: Article

References (60)

1. Ernster V.L., Ballard-Barbash R., Barlow W.E., et al. Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst 94 (2002) 1546-1554
2. Bijker N., Rutgers E.J., Peterse J.L., et al. Variations in diagnostic and therapeutic procedures in a multicentre, randomized clinical trial (EORTC 10853) investigating breast-conserving treatment for DCIS. Eur J Surg Oncol 27 (2001) 135-140
3. Fisher B., Bauer M., Margolese R., et al. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med 312 (1985) 665-673
4. Houghton J., George W.D., Cuzick J., et al. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet. 362 (2003) 95-102
5. Julien J.P., Bijker N., Fentiman I.S., et al. Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. Lancet. 355 (2000) 528-533
6. Fisher B., Dignam J., Wolmark N., et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 16 (1998) 441-452
7. Nofech-Mozes S., Spayne J., Rakovitch E., et al. Prognostic and predictive molecular markers in DCIS: a review. Adv Anat Pathol 12 (2005) 256-264
8. Nelson A.R., Fingleton B., Rothenberg M.L., et al. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 18 (2000) 1135-1149
9. Egeblad M., and Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2 (2002) 161-174
10. Manes S., Llorente M., Lacalle R.A., et al. The matrix metalloproteinase-9 regulates the insulin-like growth factor-triggered autocrine response in DU-145 carcinoma cells. J Biol Chem 274 (1999) 6935-6945
11. Noe V., Fingleton B., Jacobs K., et al. Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J Cell Sci 114 (2001) 111-118
12. Rifkin D.B., Mazzieri R., Munger J.S., et al. Proteolytic control of growth factor availability. Apmis 107 (1999) 80-85
13. Sternlicht M.D., and Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17 (2001) 463-516
14. Turk V., Kos J., and Turk B. Cysteine cathepsins (proteases)-on the main stage of cancer?. Cancer Cell 5 (2004) 409-410
15. Fingleton B., Vargo-Gogola T., Crawford H.C., et al. Matrilysin [MMP-7] expression selects for cells with reduced sensitivity to apoptosis. Neoplasia 3 (2001) 459-468
16. Stetler-Stevenson W.G. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest 103 (1999) 1237-1241
17. Yu Q., and Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 14 (2000) 163-176
18. Cornelius L.A., Nehring L.C., Harding E., et al. Matrix metalloproteinases generate angiostatin: effects on neovascularization. J Immunol 161 (1998) 6845-6852
19. Dong Z., Kumar R., Yang X., et al. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell 88 (1997) 801-810
20. Ferreras M., Felbor U., Lenhard T., et al. Generation and degradation of human endostatin proteins by various proteinases. FEBS Lett 486 (2000) 247-251
21. Baker A.H., George S.J., Zaltsman A.B., et al. Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3. Br J Cancer 79 (1999) 1347-1355
22. Jiang Y., Goldberg I.D., and Shi Y.E. Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 21 (2002) 2245-2252
23. Baker E.A., Stephenson T.J., Reed M.W., et al. Expression of proteinases and inhibitors in human breast cancer progression and survival. Mol Pathol 55 (2002) 300-304
24. Duffy M.J., Maguire T.M., Hill A., et al. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res 2 (2000) 252-257
25. Grieu F., Li W.Q., and Iacopetta B. Genetic polymorphisms in the MMP-2 and MMP-9 genes and breast cancer phenotype. Breast Cancer Res Treat 88 (2004) 197-204
26. Jones J.L., Glynn P., and Walker R.A. Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas. J Pathol 189 (1999) 161-168
27. Li H.C., Cao D.C., Liu Y., et al. Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma. Breast Cancer Res Treat 88 (2004) 75-85
28. Sivula A., Talvensaari-Mattila A., Lundin J., et al. Association of cyclooxygenase-2 and matrix metalloproteinase-2 expression in human breast cancer. Breast Cancer Res Treat 89 (2005) 215-220
29. Talvensaari-Mattila A., Paakko P., Blanco-Sequeiros G., et al. Matrix metalloproteinase-2 (MMP-2) is associated with the risk for a relapse in postmenopausal patients with node-positive breast carcinoma treated with antiestrogen adjuvant therapy. Breast Cancer Res Treat 65 (2001) 55-61
30. Talvensaari-Mattila A., Paakko P., and Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. Br J Cancer 89 (2003) 1270-1275
31. Chantrain C.F., Shimada H., Jodele S., et al. Stromal matrix metalloproteinase-9 regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment. Cancer Res 64 (2004) 1675-1686
32. Pellikainen J.M., Ropponen K.M., Kataja V.V., et al. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clin Cancer Res. 10 (2004) 7621-7628
33. Vizoso F.J., Gonzalez L.O., Corte M.D., et al. Study of matrix metalloproteinases and their inhibitors in breast cancer. Br J Cancer 96 (2007) 903-911
34. Mimori K., Ueo H., Shirasaka C., et al. Clinical significance of MT1-MMP mRNA expression in breast cancer. Oncol Rep 8 (2001) 401-403
35. Nielsen B.S., Rank F., Lopez J.M., et al. Collagenase-3 expression in breast myofibroblasts as a molecular marker of transition of ductal carcinoma in situ lesions to invasive ductal carcinomas. Cancer Res 61 (2001) 7091-7100
36. McCarthy K., Maguire T., McGreal G., et al. High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer. Int J Cancer 84 (1999) 44-48
37. Nakopoulou L., Giannopoulou I., Stefanaki K., et al. Enhanced mRNA expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in breast carcinomas is correlated with adverse prognosis. J Pathol 197 (2002) 307-313
38. Ree A.H., Florenes V.A., Berg J.P., et al. High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases. Clin Cancer Res 3 (1997) 1623-1628
39. Schrohl A.S., Christensen I.J., Pedersen A.N., et al. Tumor tissue concentrations of the proteinase inhibitors tissue inhibitor of metalloproteinases-1 (TIMP-1) and plasminogen activator inhibitor type 1 (PAI-1) are complementary in determining prognosis in primary breast cancer. Mol Cell Proteomics 2 (2003) 164-172
40. Schrohl A.S., Holten-Andersen M.N., Peters H.A., et al. Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer. Clin Cancer Res 10 (2004) 2289-2298
41. Remacle A., McCarthy K., Noel A., et al. High levels of TIMP-2 correlate with adverse prognosis in breast cancer. Int J Cancer 89 (2000) 118-121
42. Visscher D.W., Hoyhtya M., Ottosen S.K., et al. Enhanced expression of tissue inhibitor of metalloproteinase-2 (TIMP-2) in the stroma of breast carcinomas correlates with tumor recurrence. Int J Cancer 59 (1994) 339-344
43. Lebeau A., Nerlich A.G., Sauer U., et al. Tissue distribution of major matrix metalloproteinases and their transcripts in human breast carcinomas. Anticancer Res 19 (1999) 4257-4264
44. Polette M., Clavel C., Cockett M., et al. Detection and localization of mRNAs encoding matrix metalloproteinases and their tissue inhibitor in human breast pathology. Invasion Metastasis 13 (1993) 31-37
45. Kim H.J., Park C.I., Park B.W., et al. Expression of MT-1 MMP, MMP2, MMP9 and TIMP2 mRNAs in ductal carcinoma in situ and invasive ductal carcinoma of the breast. Yonsei Med J. 47 (2006) 333-342
46. Gonzalez L., Corte M.D., Vazquez J., et al. Study of matrix metalloproteinases and their tissular inhibitors in ductal "in situ" carcinomas of the breast. Histopathology (2008) [in press]
47. Gonzalez L.O., Pidal I., Junquera S., et al. Overexpression of matrix metalloproteinases and their inhibitors in mononuclear inflammatory cells in breast cancer correlates with metastasis-relapse. Br J Cancer 97 (2007) 957-963
48. Consensus conference on the classification of ductal carcinoma in situ. Hum Pathol 28 (1997) 1221-1225
49. Silverstein M.J., Poller D.N., Waisman J.R., et al. Prognostic classification of breast ductal carcinoma-in-situ. Lancet 345 (1995) 1154-1157
50. Dixon A.R., Ellis I.O., Elston C.W., et al. A comparison of the clinical metastatic patterns of invasive lobular and ductal carcinomas of the breast. Br J Cancer 63 (1991) 634-635
51. Allred D.C., Harvey J.M., Berardo M., et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11 (1998) 155-168
52. Parker R.L., Huntsman D.G., Lesack D.W., et al. Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray. Am J Clin Pathol 117 (2002) 723-728
53. Freije J.M., Diez-Itza I., Balbin M., et al. Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas. J Biol Chem 269 (1994) 16766-16773
54. Knauper V., Cowell S., Smith B., et al. The role of the C-terminal domain of human collagenase-3 (MMP-13) in the activation of procollagenase-3, substrate specificity, and tissue inhibitor of metalloproteinase interaction. J Biol Chem 272 (1997) 7608-7616
55. Knauper V., Lopez-Otin C., Smith B., et al. Biochemical characterization of human collagenase-3. J Biol Chem 271 (1996) 1544-1550
56. Strongin A.Y., Collier I., Bannikov G., et al. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem. 270 (1995) 5331-5338
57. Wang F., Reierstad S., and Fishman D.A. Matrilysin over-expression in MCF-7 cells enhances cellular invasiveness and pro-gelatinase activation. Cancer Lett 236 (2006) 292-301
58. Brinckerhoff C.E., Rutter J.L., and Benbow U. Interstitial collagenases as markers of tumor progression. Clin Cancer Res 6 (2000) 4823-4830
59. Kang Y., Siegel P.M., Shu W., et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3 (2003) 537-549
60. Black M.M., Zachrau R.E., Hankey B.F., et al. Prognostic significance of in situ carcinoma associated with invasive breast carcinoma. A natural experiment in cancer immunology. Cancer 78 (1996) 778-788